ALDOXORUBICIN
ALDOXORUBICIN 性质
| 密度 | 1.60±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -80°, stored under nitrogen,unstable in solution, ready to use. |
| 溶解度 | 二甲基亚砜：75 mg/mL（99.90 mM） |
| 酸度系数(pKa) | 7.36±0.60(Predicted) |
ALDOXORUBICIN 用途与合成方法
|
Topoisomerase II
|
Daunorubicins/Doxorubicins
|
Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion.
Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models.
ALDOXORUBICIN 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-16261 | ALDOXORUBICIN | 1361644-26-9 | 5mg | 1200 |
| 2024-04-30 | HY-16261 | ALDOXORUBICIN | 1361644-26-9 | 10mg | 1740 |
